Literature DB >> 16430869

Agonist potency differentiates G protein activation and Ca2+ signalling by the orexin receptor type 1.

Johanna Magga1, Genevieve Bart, Christian Oker-Blom, Jyrki P Kukkonen, Karl E O Akerman, Johnny Näsman.   

Abstract

The G protein coupling characteristics of a flag epitope-tagged orexin receptor type 1 (OX1R) was investigated in HEK293 cells. Immunoprecipitation of the OX1R and immunoblotting revealed interactions with Gq/G11 proteins as well as with Gs and Gi proteins. Stimulation with orexin-A did not affect the ability of the OX1R to coprecipitate Gq/G11 proteins, but it robustly elevated the intracellular concentration of Ca2+, [Ca2+]i. No changes in cAMP levels could be detected upon receptor stimulation. To get further insight into the functional correlation of G protein activation and Ca2+ signalling, we used baculovirus transduction to express chimeric G proteins, containing the Galphas protein backbone with various Galpha donor sequences (Galphas/x) at the N and C termini, and measured cAMP as functional output. The Galphas/x chimeric proteins with Galpha11(Galphaq) and Galpha16 structure in the C terminus were stimulated by the OX1R. Concentration-response curves with Galphas/16 revealed an agonist potency correlation between G protein activation and the elevation of [Ca2+]i via discharge of intracellular Ca2+ stores, a feature also recognized for the muscarinic M3 receptor. However, in contrast to the M3 receptor, the OX1R elevated [Ca2+]i via influx from extracellular space at about 30-fold lower agonist concentration. The results suggest that the OX1R is linked to influx of Ca2+ through a signal pathway independent of Gq/G11 protein activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16430869     DOI: 10.1016/j.bcp.2005.12.021

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  23 in total

1.  Regulation of OX1 orexin/hypocretin receptor-coupling to phospholipase C by Ca2+ influx.

Authors:  L Johansson; M E Ekholm; J P Kukkonen
Journal:  Br J Pharmacol       Date:  2006-11-20       Impact factor: 8.739

2.  Orexin/hypocretin receptor signalling: a functional perspective.

Authors:  C S Leonard; J P Kukkonen
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

3.  Orexin A-induced extracellular calcium influx in prefrontal cortex neurons involves L-type calcium channels.

Authors:  J X Xia; S Y Fan; J Yan; F Chen; Y Li; Z P Yu; Z A Hu
Journal:  J Physiol Biochem       Date:  2009-06       Impact factor: 4.158

Review 4.  Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?

Authors:  Shaun Yon-Seng Khoo; Robyn Mary Brown
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

Review 5.  Hypothalamic neuropeptide signaling in alcohol addiction.

Authors:  Jessica R Barson; Sarah F Leibowitz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-02-14       Impact factor: 5.067

Review 6.  Orexin/Hypocretin System: Role in Food and Drug Overconsumption.

Authors:  Jessica R Barson; Sarah F Leibowitz
Journal:  Int Rev Neurobiol       Date:  2017-08-08       Impact factor: 3.230

Review 7.  Role of orexin receptors in obesity: from cellular to behavioral evidence.

Authors:  C E Perez-Leighton; T A Butterick-Peterson; C J Billington; C M Kotz
Journal:  Int J Obes (Lond)       Date:  2012-03-06       Impact factor: 5.095

Review 8.  Orexin/hypocretin receptor signalling cascades.

Authors:  J P Kukkonen; C S Leonard
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 9.  Orexin/hypocretin and dysregulated eating: Promotion of foraging behavior.

Authors:  Jessica R Barson
Journal:  Brain Res       Date:  2018-08-17       Impact factor: 3.252

10.  Orexins stimulate steroidogenic acute regulatory protein expression through multiple signaling pathways in human adrenal H295R cells.

Authors:  Manjunath Ramanjaneya; Alex C Conner; Jing Chen; Peter R Stanfield; Harpal S Randeva
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.